Effect of contrast-enhanced ultrasound transrectal targeted prostate biopsy in patients with PSA4-10 ng/ml

doi:10.3877/cma.j.issn.1674-3253.2023.01.008

Abstract

Abstract:

Objective

To investigate the role of contrast-enhanced ultrasound transrectal targeted prostate biopsy(CETRUS-PB) in patients with PSA 4-10 ng/ml.

Methods

82 patients with PSA 4-10 ng/ml were divided into two groups on a voluntary basis: systematic transrectal ultrasound prostate biopsy (STRUS-PB) group and CETRUS-PB group from January 2016 to December 2018 in Central Hospital of Panyu District. The biopsy efficiency, VAS and complications were compared between the two groups.

Results

The positive rate of STRUS-PB group and CETRUS-PB group in PSA 4-10 ng/ml patients had no significant difference (P=0.147). There was significant difference in the number of biopsy needles, Gleason score and VAS between the two groups (P<0.001). There was no serious complications in both groups.

Conclusions

In patients with PSA 4-10 ng/ml, CETRUS-PB can not significantly improve the positive rate of prostate biopsy compared with STRUS-PB, but it may improve the accuracy of biopsy, reduce the number of biopsy needles and reduce pain.

Key words: Biopsy, Prostate cancer, Diagnosis gray area, PSA gray area

Guoqiang Qin, Xu Lu, Chaofeng Zhang, Xin Luo, Jiexian Li, Ge Zou, Funeng Jiang. Effect of contrast-enhanced ultrasound transrectal targeted prostate biopsy in patients with PSA4-10 ng/ml[J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(01): 36-38.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2023.01.008

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2023/V17/I01/36

Figures/Tables 2

References 14

[1]	杨锐林, 姚伟祥, 叶旭莹, 等. 经直肠超声造影靶向前列腺穿刺活检在PSA水平为４~20 ng/ml患者中的作用[J]. 现代泌尿生殖肿瘤杂志, 2016, 2(8): 19-23。
[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34．
[3]	Freddie B, Jacques F, Isabelle S, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[4]	Chen WQ, Zheng RS, Peter DBaade, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[5]	Gu XY, Zheng RS, Zhang SW, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Chin J Prevent Med, 2018, 52(6): 586-592.
[6]	Choi MH, Lee YJ, Jung SE. The role of transrectal ultrasound for finding focal lesions in prostate cancer detection compared to systematic sextant biopsy[J]. Acad Radiol, 2019, 26(8): 1023-1029．
[7]	Oliyide AE, Tijani KH, Jeje EA, et al. The role of transrectal ultrasound-guided fine-needle aspiration biopsy in the diagnosis of prostate cancer: Sextant versus extended protocol[J]. Niger Postgrad Med J, 2017, 24(4): 236-239．
[8]	张凯, 张志鹏, 朱刚, 等. 两种核磁靶向穿刺诊断有临床意义前列腺癌精确性的比较[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(5): 293-296.
[9]	张明博, 罗渝昆, 张艳, 等. 经直肠多模态超声影像评分系统诊断前列腺癌的临床研究[J]. 中华医学超声杂志：电子版, 2019, 16(1): 66-71．
[10]	梁丹艳, 刘倩, 吴国柱, 等. 超声造影诊断前列腺癌的Meta分析[J]. 临床超声医学杂志, 2019, 2l(9): 65l-655．
[11]	Passoni NM, Polascik TJ. Targeted prostate biopsies:the complexity behind a simple concept[J]. Eur Urol, 2014, 66(1): 30-31.
[12]	Zhao HX, Xia CX, Yin HX, et al. The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer[J]. Eur J Radiol, 2013, 82(11): e641-e647.
[13]	林思杰, 吴杰英, 陆敏华, 等. 局部浸润麻醉与黏膜表面麻醉在经直肠超声引导前列腺穿刺活检中的应用比较[J/CD].中华腔镜泌尿外科杂志(电子版), 2020, 14(1): 4-7.
[14]	钟婉媚, 莫承强, 罗俊航, 等. 902例超声引导下经直肠前列腺穿刺的并发症分析及处理[J/CD].中华腔镜泌尿外科杂志(电子版), 2018, 12(2): 83-85.

组别	例数	年龄(岁)	tPSA(ng/ml)	f/t比值	前列腺体积(ml)
造影组	32	69±7	6.9±1.6	0.16±0.07	86±44
系统组	50	68±9	7.2±1.7	0.16±0.08	75±39
统计值		-0.458	0.717	0.422	-1.112
P值		0.648	0.475	0.674	0.269

组别	例数	年龄(岁)	tPSA(ng/ml)	f/t比值	前列腺体积(ml)
造影组	32	69±7	6.9±1.6	0.16±0.07	86±44
系统组	50	68±9	7.2±1.7	0.16±0.08	75±39
统计值		-0.458	0.717	0.422	-1.112
P值		0.648	0.475	0.674	0.269

组别	例数	穿刺阳性[例(%)]	穿刺针数[针，(±s)]	Gleason评分[M(Q₁，Q₃)]	VAS[分，(±s)]
造影组	32	6(18.75)	8.8±0.9	7(6，8)	1.3±0.5
系统组	50	4(8.00)	13.0±0.0	6(6，6)	4.1±0.6
统计值		χ²=2.106	t=-25.44	Z=-3.926	t=-21.168
P值		0.147	<0.001	<0.001	<0.001

组别	例数	穿刺阳性[例(%)]	穿刺针数[针，(±s)]	Gleason评分[M(Q₁，Q₃)]	VAS[分，(±s)]
造影组	32	6(18.75)	8.8±0.9	7(6，8)	1.3±0.5
系统组	50	4(8.00)	13.0±0.0	6(6，6)	4.1±0.6
统计值		χ²=2.106	t=-25.44	Z=-3.926	t=-21.168
P值		0.147	<0.001	<0.001	<0.001

[1]	Ye Fang, Xiaohong Xie, Hui Luo. Application of quality control circle in improving prostate cancer detection rate by puncture biopsy [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(07): 722-727.
[2]	Jianhui Cao, Dong Xu, Bin Feng, Junbiao Zheng, Weiwei Huang. Application value of contrast-enhanced ultrasound in prostate cancer biopsy in patients with different prostate specific antigen levels [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(03): 307-312.
[3]	Jun Li, Jianyun Peng, Wanbing Qiu, Qianyi Dou, Fushun Pan, Jinyu Liang. Risk stratification of malignant thyroid nodules (guidelines): A comparative study of diagnostic efficacy of ACR TI-RADS versus C-TIRADS and consistency of guideline application by different physicians [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 401-407.
[4]	Quanxi Li, Huijun Tang, Jiansheng Zhang, Fei Yang. Comparative study of multiplexed sensitivity-encoding diffusion weighted imaging and single-shot echo-planar diffusion weighted imaging in prostate cancer images [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 553-557.
[5]	Tengcheng Li, Yiyuan Tan, Qunxiong Huang, Jieying Wu, Hengjun Xiao, Cheng Hu, Maoyin Li, Xin Gao, Jinming Di. Robot-assisted radical prostatectomy via posterior and completely intrafascial for organ-confined prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(05): 452-456.
[6]	Jinyi Mei, Yan Wang, Min Qu, Zhenyang Dong, Zenghui Zhou, Xianqi Shen, Jialun Li, Xu Gao. The treatment of "extra-vesicle median lobe" in robotic radical prostatectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(05): 429-433.
[7]	Jingjun Mu, Zengni Ma, Xiaoming Cao. Analysis of risk factors for extraprostatic extension in clinically localized prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(04): 326-331.
[8]	Quanxi Li, Huijun Tang, Youjie Tang, Fei Yang. Application value of DISCO imaging in differential diagnosis of benign prostatic hyperplasia and prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(04): 332-335.
[9]	Bangyu Wang, Xiaopeng Chen, Guojun Tang, Jiani Wang. A preliminary study of the diagnostic value of urine extracellular vesicle circRNA classifier for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(04): 339-342.
[10]	Shuoru Liu, Gongwei Wang, Bin Zhang, Shuhao Li, Cheng Hu. Oncolytic virus M1 activates endoplasmic reticulum stress pathway to induce apoptosis of prostate cancer cells [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(04): 388-393.
[11]	Jiayu Zheng, Jianjie Wu, Xiaojuan Li, Hengda Zeng, Guobang Li, Jiongduan Huang, Xingqiao Wen. Expression of hsa_circ_0090923 in prostate cancer and its effect on the proliferation and migration of prostate cancer cells [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(03): 276-283.
[12]	Xingli Shan, Dong Wang, Nianzeng Xing, Zejun Xiao, Yajian Li. Diagnostic value of ⁶⁸Ga-PSMA-PET /CT in pelvic lymph node metastasis of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(03): 214-218.
[13]	Chufeng Wang, An Jiang. Molecular diagnosis of primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 499-503.
[14]	Yimin E, Sizheng Sun, Xiaoyu Fan, Chunzhao Yu. Present status and prospect of fecal screening for colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(04): 331-336.
[15]	Sugui Wang, Liyuan Huang, Fujin Jiang, Ziyu Wu, Xianyun Zhang, Qiang Li, Dali Yan. Role of HNRNPA2B1 in prostate cancer and screening of HNRNPA2B1-targeted active components of traditional Chinese medicine [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 731-736.

Please choose a citation manager

Content to export